A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Siltuximab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2008 Checked against clinicaltrials.gov record, last updated 16 Oct 2008.